In April of this year, Takeda Pharmaceutical, Japan’s largest drug company purchased Millennium Pharmaceuticals, one of the earliest American genomics companies for nearly $9 billion providing Takeda an entry into the cancer-drug market. During this off-the-record discussion, topics will include:
- Important criteria each company sought in a strategic partner
- Communicating effectively through cultural differences
- Lessons learned during the due diligence process
- Approach for successful integration of the two companies
Presenters included:
- Gabor Garai, Co-Chair, Life Sciences Industry Team, Foley
- Dr. Daniel Curran, Vice President, Corporate Development, Millennium Pharmaceuticals Inc.
- Catherine Sazdanoff, Vice President, Global Licensing, Takeda Pharmaceuticals North America, Inc.
Related Insights
July 11, 2025
Foley Viewpoints
Department of Justice Launches Program to Reward Antitrust Whistleblowers with Shares of Criminal Fines
On July 8, 2025, the U.S. Department of Justice, Antitrust Division (“Antitrust Division”) announced a new “Whistleblower Rewards…
July 23, 2025
Events
Healthcare Supply Chain Compliance Challenges: Vendor Management, Contract Negotiation, Tariff Impact
Foley partner Monica Chmielewski, vice chair of the firm’s Health Care Practice Group, is speaking in Strafford’s upcoming webinar titled “Healthcare Supply Chain Compliance Challenges: Vendor Management, Contract Negotiation, Tariff Impact” on July 23.
September 30, 2025
Events
FDA Regulation of AI-Enabled Medical Devices
Foley partner Kyle Faget, co-chair of the firm’s Medical Devices Area of Focus, is speaking at the American Bar Association Health Law Section’s Healthcare Delivery & Innovation Conference on September 30.